Adenosine signaling: Optimal target for gastric cancer immunotherapy
Gastric cancer (GC) is one of the most common malignancy and leading cause of cancer-related deaths worldwide. Due to asymptomatic or only nonspecific early symptoms, GC patients are usually in the advanced stage at first diagnosis and miss the best opportunity of treatment. Immunotherapies, especia...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1027838/full |
| _version_ | 1797995224356618240 |
|---|---|
| author | Junqing Wang Linyong Du Xiangjian Chen |
| author_facet | Junqing Wang Linyong Du Xiangjian Chen |
| author_sort | Junqing Wang |
| collection | DOAJ |
| description | Gastric cancer (GC) is one of the most common malignancy and leading cause of cancer-related deaths worldwide. Due to asymptomatic or only nonspecific early symptoms, GC patients are usually in the advanced stage at first diagnosis and miss the best opportunity of treatment. Immunotherapies, especially immune checkpoint inhibitors (ICIs), have dramatically changed the landscape of available treatment options for advanced-stage cancer patients. However, with regards to existing ICIs, the clinical benefit of monotherapy for advanced gastric cancer (AGC) is quite limited. Therefore, it is urgent to explore an optimal target for the treatment of GC. In this review, we summarize the expression profiles and prognostic value of 20 common immune checkpoint-related genes in GC from Gene Expression Profiling Interactive Analysis (GEPIA) database, and then find that the adenosinergic pathway plays an indispensable role in the occurrence and development of GC. Moreover, we discuss the pathophysiological function of adenosinergic pathway in cancers. The accumulation of extracellular adenosine inhibits the normal function of immune effector cells and facilitate the effect of immunosuppressive cells to foster GC cells proliferation and migration. Finally, we provide insights into potential clinical application of adenosinergic-targeting therapies for GC patients. |
| first_indexed | 2024-04-11T09:58:06Z |
| format | Article |
| id | doaj.art-2d64f95250d3440e89c12ec56e9dddf6 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T09:58:06Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2d64f95250d3440e89c12ec56e9dddf62022-12-22T04:30:30ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.10278381027838Adenosine signaling: Optimal target for gastric cancer immunotherapyJunqing Wang0Linyong Du1Xiangjian Chen2School of the 1St Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, ChinaKey Laboratory of Laboratory Medicine, Ministry of Education of China, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, ChinaSchool of the 1St Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, ChinaGastric cancer (GC) is one of the most common malignancy and leading cause of cancer-related deaths worldwide. Due to asymptomatic or only nonspecific early symptoms, GC patients are usually in the advanced stage at first diagnosis and miss the best opportunity of treatment. Immunotherapies, especially immune checkpoint inhibitors (ICIs), have dramatically changed the landscape of available treatment options for advanced-stage cancer patients. However, with regards to existing ICIs, the clinical benefit of monotherapy for advanced gastric cancer (AGC) is quite limited. Therefore, it is urgent to explore an optimal target for the treatment of GC. In this review, we summarize the expression profiles and prognostic value of 20 common immune checkpoint-related genes in GC from Gene Expression Profiling Interactive Analysis (GEPIA) database, and then find that the adenosinergic pathway plays an indispensable role in the occurrence and development of GC. Moreover, we discuss the pathophysiological function of adenosinergic pathway in cancers. The accumulation of extracellular adenosine inhibits the normal function of immune effector cells and facilitate the effect of immunosuppressive cells to foster GC cells proliferation and migration. Finally, we provide insights into potential clinical application of adenosinergic-targeting therapies for GC patients.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1027838/fullgastric cancerCD39CD73adenosineimmunotherapy |
| spellingShingle | Junqing Wang Linyong Du Xiangjian Chen Adenosine signaling: Optimal target for gastric cancer immunotherapy Frontiers in Immunology gastric cancer CD39 CD73 adenosine immunotherapy |
| title | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
| title_full | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
| title_fullStr | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
| title_full_unstemmed | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
| title_short | Adenosine signaling: Optimal target for gastric cancer immunotherapy |
| title_sort | adenosine signaling optimal target for gastric cancer immunotherapy |
| topic | gastric cancer CD39 CD73 adenosine immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1027838/full |
| work_keys_str_mv | AT junqingwang adenosinesignalingoptimaltargetforgastriccancerimmunotherapy AT linyongdu adenosinesignalingoptimaltargetforgastriccancerimmunotherapy AT xiangjianchen adenosinesignalingoptimaltargetforgastriccancerimmunotherapy |